DEF: Evofem Seeks Reverse Stock Split Amid Financial Challenges

Evofem Biosciences, a women's health company, is seeking stockholder approval for a reverse stock split to meet Nasdaq listing standards and enable a critical capital raise, following a year of mixed financial performance and a terminated merger.

Summary

• Evofem Biosciences is committed to commercializing innovative products addressing unmet needs in women's sexual and reproductive health, focusing on PHEXX and SOLOSEC.
• PHEXX, a hormone-free contraceptive vaginal gel, achieved its fourth consecutive year of increased net product sales in 2024, a trend expected to continue in 2025, despite modest growth due to fiscal austerity measures.
• The company acquired global rights to SOLOSEC (secnidazole) 2g oral granules in July 2024, re-launched it in November 2024, and it is exceeding projections for treating bacterial vaginosis (BV) and trichomoniasis.
• An investigator-led study in 2025 found once-weekly SOLOSEC effective for recurrent BV, potentially surpassing current CDC-recommended treatments, and an NIH-funded Phase 4 study for trichomoniasis hypothesizes lower repeat infections and better cost-effectiveness compared to metronidazole.
• Evofem expanded globally by closing two transactions in the past 15 months for PHEXX and SOLOSEC commercial rights in the Middle East and North Africa (MENA) region, with launches expected in the UAE in 2026.
• Cost reduction initiatives are underway, aiming to cut PHEXX cost of goods (COGs) by over 55% and SOLOSEC COGs by at least 50% starting in 2027.
• The merger with Aditxt, Inc. was terminated in October 2025, and the company is now pursuing a new path to re-list its stock on Nasdaq or a comparable national market and complete a fundraising round.
• A reverse stock split at a ratio between 1-for-500 and 1-for-1,500 is proposed to increase the share price and meet Nasdaq listing standards, which is deemed critically important for the company's future.
• The company expects to be EBITDA positive on a sustainable basis in 2027 and beyond, contingent on appropriate growth capital and successful execution of its commercial strategy.
• The Annual Meeting of Stockholders on November 26, 2025, will address director elections, executive compensation, approval of the 2025 Equity Incentive Plan, the reverse stock split, auditor ratification, and potential adjournment.

Sentiment

Score: 3

Explanation: While the company highlights product growth and strategic initiatives for global expansion and cost reduction, these positives are significantly overshadowed by severe financial distress. The $0.01 stock price, a substantial net loss in 2024, the critical need for a reverse stock split to avoid default on debt covenants and enable fundraising, and the termination of a key merger, all point to a highly challenging and precarious situation. The high risk of further dilution and potential cessation of operations contribute to a low sentiment.

Positives

• Achieved its fourth consecutive year of increased net product sales for PHEXX in 2024, with this trend expected to continue in 2025.
• Acquired global rights to SOLOSEC in July 2024, adding a valuable and synergistic sexual health asset to the commercial portfolio.
• SOLOSEC's re-launch in November 2024 is exceeding projections, indicating strong market acceptance.
• An investigator-led study in 2025 found once-weekly SOLOSEC effective for recurrent BV, potentially matching or surpassing current CDC-recommended suppressive treatments.
• An NIH-funded Phase 4 study for trichomoniasis hypothesizes SOLOSEC will have a 1.75 lower rate of repeat infections and be more cost-effective than multi-dose metronidazole.
• Successfully closed two transactions for PHEXX and SOLOSEC commercial rights in the MENA region, with launches and revenues expected in the UAE in 2026.
• Implementing cost reduction initiatives for PHEXX (over 55% COGs reduction) and SOLOSEC (at least 50% COGs reduction by 2027) to improve profitability.
• Management expects a full payout of the potential cash incentive bonus for 2024 due to the achievement of weighted performance objectives.

Negatives

• PHEXX growth has been modest due to ongoing fiscal austerity measures, limiting investment in sales and marketing.
• The current Common Stock trading price is $0.01 per share, necessitating a reverse stock split to meet Nasdaq listing standards.
• The merger with Aditxt, Inc. was terminated in October 2025, representing a significant strategic setback.
• Net income (loss) for 2024 was $(8,860) thousand, a substantial decline from $52,979 thousand in 2023.
• The company's fully diluted capital structure is well above the authorized common shares, creating a risk of liability and potential default under debt arrangements.
• No equity awards were granted to employees or named executive officers in 2023 or 2024 due to the low stock price.
• Non-employee director fees totaling $0.5 million for 2024 have not been paid quarterly and are recorded as accrued expenses.

Risks

• The proposed Reverse Stock Split may not result in a sustained increase in the per share price of Common Stock.
• The liquidity of Common Stock could be adversely affected by the reduced number of shares outstanding after the Reverse Stock Split.
• The increased proportion of unissued authorized shares to issued shares after the Reverse Stock Split may have anti-takeover effects.
• Failure to approve and effectuate the Reverse Stock Split could trigger an event of default and other adverse events under the company's debt obligations.
• Default obligations could adversely affect results of operations, impair the ability to raise capital, and may require the company to cease operations entirely.
• Stockholders may not receive any value for their shares if the company is forced to cease operations.
• Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations.
• Risks are related to obtaining stockholder approval for the proposals, the ability to implement corporate actions such as the reverse stock split or equity incentive plans, and access to capital markets.

Future Outlook

The company expects continued year-over-year net product sales growth for PHEXX in 2025 and anticipates SOLOSEC to continue exceeding projections. It looks forward to the publication of the recurrent BV study and the launch and revenues from both PHEXX and SOLOSEC in the UAE in 2026. Cost of goods for SOLOSEC are expected to be cut by at least 50% beginning in 2027. The company aims to re-list its stock on Nasdaq or a comparable national market and complete a fundraising round to provide critical capital. With appropriate growth capital and successful execution of its commercial strategy, the company expects to be EBITDA positive on a sustainable basis in 2027 and beyond.

Management Comments

• "Evofem continues to execute our strategy to increase net product sales year over year."
• "2024 was our fourth consecutive year of increased net product sales, and we expect this trend to continue in 2025."
• "It is a testament to the creativity and tenacity of our commercial team that PHEXX has held its market share and net sales have increased each and every year since launch."
• "SOLOSEC continues to grow and to exceed our projections."
• "We look forward to publication of this study [recurrent BV] in a peer-reviewed journal in due course."
• "We look forward to supporting the launch of – and revenues from – both products in the UAE in 2026."
• "We intend to continue exploring additional opportunities to further expand the global reach of our products and maximize their global potential."
• "Growing product sales is only part of the equation for Evofem’s long-term success; we have prioritized reducing cost of goods for both PHEXX and SOLOSEC."
• "With the appropriate growth capital and successful execution of our commercial strategy, we expect to be EBITDA positive on a sustainable basis in 2027 and beyond."
• "A critical first step is that to meet Nasdaq listing standards, we must increase our share price."
• "Approval of the reverse split is critically important to Evofem’s future."

Industry Context

Evofem Biosciences operates in the women's sexual and reproductive health sector, addressing significant unmet needs with its hormone-free contraceptive PHEXX and single-dose treatments for common sexual health conditions, SOLOSEC. The company's focus on hormone-free options and single-dose therapies positions it to address patient preferences for fewer side effects and improved treatment compliance, particularly relevant in conditions like bacterial vaginosis (affecting 23-29% of women globally) and trichomoniasis (156.3 million new cases worldwide annually). The strategy to target women using GLP-1 medications for weight loss with PHEXX demonstrates an adaptive approach to emerging market trends and potential drug interactions with traditional oral contraceptives.

Comparison to Industry Standards

• Executive compensation target goal was initially set at the 75th percentile of a peer group of early-stage commercialization pharmaceutical companies, but was later lowered to the 50th percentile for on-target performance, indicating a recalibration of compensation strategy relative to industry benchmarks.
• SOLOSEC's once-weekly dosing for recurrent bacterial vaginosis demonstrated efficacy matching or potentially surpassing outcomes of current CDC-recommended suppressive treatments, such as metronidazole which requires 14 doses over seven days, suggesting a competitive advantage in treatment regimen and compliance.
• An NIH-funded Phase 4 study is evaluating SOLOSEC against metronidazole for trichomoniasis, hypothesizing a 1.75 lower rate of repeat infections and greater cost-effectiveness for single-dose SOLOSEC compared to multi-dose metronidazole, indicating a potential to redefine standard of care and improve patient outcomes relative to existing therapies.

Management Changes

Corporate Governance

Related Party Transactions

• On April 8, 2025, and June 26, 2025, the company entered into securities purchase agreements with Aditxt, Inc., providing for the sale and issuance of senior subordinated convertible notes (Aditxt Notes) totaling $3.7 million in aggregate original principal amount and warrants to purchase 242,257,742 shares of Common Stock. Net proceeds to the company were approximately $2.4 million.
• Aditxt, Inc. holds 26,280 shares of Series F-1 Preferred Stock and notes/warrants convertible into a significant number of Common Stock shares.
• Saundra Pelletier, President and CEO, served as a director of Aditxt, Inc. until September 23, 2025, without compensation, and did not participate in Board deliberations or vote on the merger agreement with Aditxt.
• On August 7, 2023, certain investors exchanged $1.8 million in principal and accrued interest under outstanding convertible promissory notes for 1,800 shares of Series E-1 Convertible Preferred Stock.
• In August 2025, the company entered into Exchange Agreements with certain investors, exchanging approximately $1.6 million in senior secured convertible notes for 1,573 shares of Series G-1 Convertible Preferred Stock.

Stakeholder Impact

• **Shareholders**: Face significant dilution risk from potential future equity issuances and the proposed reverse stock split. The outcome of the reverse stock split and capital raise will critically impact the company's ability to re-list on Nasdaq and potentially increase share price, or risk further value erosion and cessation of operations.
• **Employees**: Eligible for the proposed 2025 Equity Incentive Plan, which could provide motivation and retention incentives. Executive compensation includes base salary and performance-based cash bonuses, with full payouts expected for 2024 performance objectives.
• **Customers (Women seeking sexual and reproductive health solutions)**: Potential for continued access to PHEXX and SOLOSEC, and the introduction of these products into new global markets, offering innovative treatment options.
• **Creditors**: The company has approximately $63.3 million in outstanding debt obligations. Failure to approve the reverse stock split and raise capital could trigger events of default, potentially impacting creditors' ability to recover their investments.
• **Suppliers**: The company is working to establish a second supplier for PHEXX and activated its contract manufacturer for SOLOSEC, indicating ongoing relationships and potential for new partnerships.

Next Steps

• Drive PHEXX growth in 2025 through social media campaigns, participation in strategic medical conferences, and initiatives targeting women using GLP-1 medications.
• Await publication of the investigator-led study on SOLOSEC for recurrent BV in a peer-reviewed journal.
• Continue the NIH-funded Phase 4 study evaluating SOLOSEC versus metronidazole for trichomoniasis.
• Support the launch of and generate revenues from PHEXX and SOLOSEC in the UAE in 2026.
• Work on subsequent regulatory filings for PHEXX and SOLOSEC in the licensed MENA territory.
• Explore additional opportunities to further expand the global reach of products.
• Establish and validate a second supplier for PHEXX manufacturing to reduce cost of goods and supply chain risk.
• Transition from selling finished goods inventory to selling new-made SOLOSEC goods in 2026, with expected COGs cuts by at least 50% starting in 2027.
• Re-list stock on the Nasdaq or a comparable national market.
• Complete a fundraising round to provide critical capital for sales and marketing initiatives.
• Stockholders to vote on six proposals, including director elections, executive compensation, the 2025 Equity Incentive Plan, and the reverse stock split, at the Annual Meeting on November 26, 2025.
• The Board may effect the Reverse Stock Split, if approved, by November 26, 2026.

Key Dates

Recommendation

The company is in a highly distressed financial state, evidenced by a $0.0099 stock price, a significant net loss of $(8,860) thousand in 2024 (a sharp decline from a positive 2023), and the critical need for a reverse stock split to avoid default on debt covenants and meet Nasdaq listing requirements. The termination of the Aditxt merger is a major strategic setback. While there are positive operational developments like product sales growth and global expansion, these are overshadowed by the existential financial challenges. The high risk of further dilution, potential cessation of operations, and the company's current valuation make it a high-risk investment with a strong likelihood of further value erosion. A seasoned investor would likely exit or avoid this stock until there is clear evidence of financial stabilization and successful execution of a sustainable turnaround strategy.

Keywords

Evofem Biosciences, EVFM, women's health, sexual health, reproductive health, PHEXX, SOLOSEC, contraceptive, bacterial vaginosis, trichomoniasis, SEC filing, proxy statement, reverse stock split, Nasdaq listing, capital raise, corporate governance, executive compensation, pharmaceutical, biotech